Search Results

Your search for Ursula A. Matulonis, MD matches 2 pages

Showing 1 - 2

By The ASCO Post Staff / 2019 SGO Annual Meeting on Womens Cancer / Tuesday, March 19, 2019 5:27 PM

SGO 2019: Treatment With Maintenance Niraparib in Recurrent Ovarian Cancer Extends Time Without Symptoms or Toxicity

Findings from a recent clinical trial presented in a Scientific Plenary session at the Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer revealed that women with recurrent ovarian cancer who received niraparib as maintenance therapy experienced more time...

breast cancer

gynecologic cancers

issues in oncology

By The ASCO Post Staff / Wednesday, April 22, 2015 12:59 PM

AACR 2015: Olaparib and Investigational PI3K Inhibitor BKM120 Combination Active Against Ovarian and Breast Cancer Subtypes

Combination treatment with the poly ADP-ribose polymerase (PARP) inhibitor olaparib (Lynparza) and the investigational phosphatidylinositol-3-kinase (PI3K) inhibitor BKM120 was safe and yielded evidence of clinical benefit for women with triple-negative breast cancer and for those with high-grade...

Apr

Today In Oncology

Search Results

Your search for Ursula A. Matulonis, MD matches 2 pages

SGO 2019: Treatment With Maintenance Niraparib in Recurrent Ovarian Cancer Extends Time Without Symptoms or Toxicity

AACR 2015: Olaparib and Investigational PI3K Inhibitor BKM120 Combination Active Against Ovarian and Breast Cancer Subtypes

FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs

AI Model May Help Predict Treatment Responses Select Most Effective Cancer Therapies in Patients With Cancer

In-Hospital Mortality Among Patients With COVID-19 Infection, With or Without Cancer

Imaging Drug to Assist in Detection of Cancerous Tissue Following Lumpectomy Approved

Potential Protective Effects of Aspirin Against Colorectal Cancer